Geron Corporation (GERN NASDAQ) stock market data APIs
$1.1584
0(0%)
as of October 27, 2026
Try our APIs with
free plan!
Geron Corporation Financial Data Overview
Price chart is built with
Anychart
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Prev. Close
1.1584
Open
1.1624
High
1.1953
Low
1.1454
52 wk Range
1.04-2.01
Market Cap
739 M
Shares Outstanding
642 M
Revenue
205 M
EPS
-0.02
Beta
0.611
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Geron Corporation (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Geron Corporation data using free add-ons & libraries
Get Geron Corporation Fundamental Data
Geron Corporation Fundamental data includes:
- Net Revenue: 205 M
- EBITDA: -34 799 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Geron Corporation News
New
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Bristol Myers BMY is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line growth amid a significant decline in legacy drug sales. These key drugs are p...
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million, toward the midpoint to high end of it...
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron expects RYTELO's 2026 revenue near the high end of its $230 million–$240 million guidance, supported by three ...
Geron to Present at Upcoming Investor Conferences
Geron Corporation FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people ...
Get Geron Corporation fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.